Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
ARCA biopharma, Inc. (ABIO)
|
Add to portfolio |
|
|
|
| Price: |
$2.21
| | Metrics |
| OS: |
14.4
|
M
| |
-40
|
% ROE
|
| Market cap: |
$31.8
|
M
| |
-1037
|
% ROIC
|
|
Net cash:
|
$42.4
|
M
| |
$2.95
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($16.9)
|
M
| |
|
|
|
EBIT
|
($16.9)
|
M
| |
|
|
| EPS |
($1.18)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 4.7 | 0.0 | 13.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | -65.7% | | | | | | |
| Cost of goods sold | 0.0 | 4.7 | 0.0 | 13.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 0.0% | | 0.0% | | | | |
| Selling, general and administrative | 10.6 | | 19.3 | | | | | |
| Research and development | | | | | 5.0 | 1.8 | 4.2 | 14.1 |
| General and administrative | | 5.8 | | 5.5 | 4.8 | 4.0 | 3.9 | 4.6 |
| EBITA | -11.3 | -10.6 | -19.3 | -19.3 | -9.8 | -5.8 | -8.1 | -18.4 |
| EBITA margin | | -223.1% | | -139.8% | | | | |
| Amortization of intangibles | | | | | | | | 0.3 |
| EBIT | -11.3 | -10.6 | -19.3 | -19.3 | -9.8 | -5.8 | -8.1 | -18.7 |
| EBIT margin | | -223.1% | | -139.8% | | | | |
| Pre-tax income | -9.9 | -9.9 | -19.3 | -19.3 | -9.7 | -5.6 | -8.0 | -18.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | -0.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 3.0% | 0.4% | 0.3% |
| Net income | -9.9 | -9.9 | -19.3 | -19.3 | -9.7 | -5.5 | -7.9 | -18.5 |
| Net margin | | -209.0% | | -139.7% | | | | |
| |
| Diluted EPS | ($0.69) | ($0.69) | ($1.39) | ($1.39) | ($2.07) | ($4.15) | ($10.31) | ($1.77) |
| Shares outstanding (diluted) | 14.4 | 14.4 | 13.9 | 13.9 | 4.7 | 1.3 | 0.8 | 10.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|